O	0	5	TBX21	TBX21	NN	B-NP
O	5	6	:	:	:	O
O	7	8	a	a	DT	B-NP
O	9	19	functional	functional	JJ	I-NP
O	20	27	variant	variant	NN	I-NP
O	28	36	predicts	predict	VBZ	B-VP
O	37	48	improvement	improvement	NN	B-NP
O	49	51	in	in	IN	B-PP
O	52	58	asthma	asthma	NN	B-NP
O	59	63	with	with	IN	B-PP
O	64	67	the	the	DT	B-NP
O	68	71	use	use	NN	I-NP
O	72	74	of	of	IN	B-PP
O	75	82	inhaled	inhale	VBN	B-NP
O	83	98	corticosteroids	corticosteroid	NNS	I-NP
O	98	99	.	.	.	O

O	100	105	TBX21	TBX21	NN	B-NP
O	106	113	encodes	encode	VBZ	B-VP
O	114	117	for	for	IN	B-PP
O	118	121	the	the	DT	B-NP
O	122	135	transcription	transcription	NN	I-NP
O	136	142	factor	factor	NN	I-NP
O	143	144	T	T	NN	I-NP
O	144	145	-	-	HYPH	O
O	145	148	bet	bet	NN	B-NP
O	149	150	(	(	(	O
O	150	151	T	T	NN	B-NP
O	151	152	-	-	HYPH	I-NP
O	152	155	box	box	NN	I-NP
O	156	165	expressed	express	VBN	B-VP
O	166	168	in	in	IN	B-PP
B-Cell	169	170	T	T	NN	B-NP
I-Cell	171	176	cells	cell	NNS	I-NP
O	176	177	)	)	)	O
O	177	178	,	,	,	O
O	179	184	which	which	WDT	B-NP
O	185	195	influences	influence	VBZ	B-VP
O	196	201	naive	naive	JJ	B-NP
B-Cell	202	203	T	T	NN	I-NP
I-Cell	204	214	lymphocyte	lymphocyte	NN	I-NP
O	215	226	development	development	NN	I-NP
O	227	230	and	and	CC	O
O	231	234	has	have	VBZ	B-VP
O	235	239	been	be	VBN	I-VP
O	240	250	implicated	implicate	VBN	I-VP
O	251	253	in	in	IN	B-PP
O	254	260	asthma	asthma	NN	B-NP
O	261	273	pathogenesis	pathogenesis	NN	I-NP
O	273	274	.	.	.	O

O	275	287	Specifically	Specifically	RB	B-ADVP
O	287	288	,	,	,	O
O	289	292	the	the	DT	B-NP
O	293	294	T	T	NN	I-NP
O	294	295	-	-	HYPH	B-NP
O	295	298	bet	bet	VBN	I-NP
O	299	307	knockout	knockout	NN	I-NP
O	308	313	mouse	mouse	NN	I-NP
O	314	327	spontaneously	spontaneously	RB	B-VP
O	328	336	develops	develop	VBZ	I-VP
B-Multi-tissue_structure	337	343	airway	airway	NN	B-NP
O	344	363	hyperresponsiveness	hyperresponsiveness	NN	I-NP
O	364	367	and	and	CC	O
O	368	373	other	other	JJ	B-NP
O	374	381	changes	change	NNS	I-NP
O	382	392	consistent	consistent	JJ	B-ADJP
O	393	397	with	with	IN	B-PP
O	398	404	asthma	asthma	NN	B-NP
O	404	405	.	.	.	O

O	406	413	Because	Because	IN	B-SBAR
B-Multi-tissue_structure	414	420	airway	airway	NN	B-NP
O	421	435	responsiveness	responsiveness	NN	I-NP
O	436	438	is	be	VBZ	B-VP
O	439	448	moderated	moderate	VBN	I-VP
O	449	451	by	by	IN	B-PP
O	452	455	the	the	DT	B-NP
O	456	459	use	use	NN	I-NP
O	460	462	of	of	IN	B-PP
O	463	470	inhaled	inhale	VBN	B-NP
O	471	486	corticosteroids	corticosteroid	NNS	I-NP
O	487	489	in	in	IN	B-PP
O	490	496	asthma	asthma	NN	B-NP
O	496	497	,	,	,	O
O	498	500	it	it	PRP	B-NP
O	501	503	is	be	VBZ	B-VP
O	504	515	conceivable	conceivable	JJ	B-ADJP
O	516	520	that	that	IN	B-SBAR
O	521	528	genetic	genetic	JJ	B-NP
O	529	538	variation	variation	NN	I-NP
O	539	541	in	in	IN	B-PP
O	542	547	TBX21	TBX21	NN	B-NP
O	548	551	may	may	MD	B-VP
O	552	557	alter	alter	VB	I-VP
O	558	564	asthma	asthma	NN	B-NP
O	565	575	phenotypes	phenotype	NNS	I-NP
O	576	578	in	in	IN	B-PP
O	579	580	a	a	DT	B-NP
O	581	590	treatment	treatment	NN	I-NP
O	590	591	-	-	HYPH	B-NP
O	591	599	specific	specific	JJ	I-NP
O	600	607	fashion	fashion	NN	I-NP
O	607	608	.	.	.	O

O	609	613	Here	Here	RB	B-ADVP
O	614	616	we	we	PRP	B-NP
O	617	628	demonstrate	demonstrate	VBP	B-VP
O	629	633	that	that	IN	B-SBAR
O	634	637	the	the	DT	B-NP
O	638	651	nonsynonymous	nonsynonymous	JJ	I-NP
O	652	661	variation	variation	NN	I-NP
O	662	664	in	in	IN	B-PP
O	665	670	TBX21	TBX21	NN	B-NP
O	671	677	coding	coding	NN	I-NP
O	678	681	for	for	IN	B-PP
O	682	693	replacement	replacement	NN	B-NP
O	694	696	of	of	IN	B-PP
O	697	706	histidine	histidine	NN	B-NP
O	707	709	33	33	CD	I-NP
O	710	714	with	with	IN	B-PP
O	715	724	glutamine	glutamine	NN	B-NP
O	725	727	is	be	VBZ	B-VP
O	728	738	associated	associate	VBN	I-VP
O	739	743	with	with	IN	B-PP
O	744	755	significant	significant	JJ	B-NP
O	756	767	improvement	improvement	NN	I-NP
O	768	770	in	in	IN	B-PP
O	771	774	the	the	DT	B-NP
O	775	777	PC	PC	NN	I-NP
O	777	778	(	(	(	O
O	778	780	20	20	CD	B-NP
O	780	781	)	)	)	O
O	782	783	(	(	(	O
O	783	784	a	a	DT	B-NP
O	785	792	measure	measure	NN	I-NP
O	793	795	of	of	IN	B-PP
B-Multi-tissue_structure	796	802	airway	airway	NN	B-NP
O	803	817	responsiveness	responsiveness	NN	I-NP
O	817	818	)	)	)	O
O	819	821	of	of	IN	B-PP
O	822	831	asthmatic	asthmatic	JJ	B-NP
O	832	840	children	child	NNS	I-NP
O	841	843	in	in	IN	B-PP
O	844	845	a	a	DT	B-NP
O	846	851	large	large	JJ	I-NP
O	852	860	clinical	clinical	JJ	I-NP
O	861	866	trial	trial	NN	I-NP
O	867	875	spanning	span	VBG	B-VP
O	876	877	4	4	CD	B-NP
O	878	883	years	year	NNS	I-NP
O	883	884	.	.	.	O

O	885	887	We	We	PRP	B-NP
O	888	892	note	note	VBP	B-VP
O	893	897	that	that	IN	B-SBAR
O	898	902	this	this	DT	B-NP
O	903	911	increase	increase	NN	I-NP
O	912	918	occurs	occur	VBZ	B-VP
O	919	923	only	only	RB	B-ADVP
O	924	926	in	in	IN	B-PP
O	927	930	the	the	DT	B-NP
O	931	939	children	child	NNS	I-NP
O	940	950	randomized	randomize	VBN	B-VP
O	951	953	to	to	TO	B-PP
O	954	961	inhaled	inhale	VBN	B-NP
O	962	977	corticosteroids	corticosteroid	NNS	I-NP
O	978	981	and	and	CC	O
O	982	986	that	that	IN	B-SBAR
O	987	989	it	it	PRP	B-NP
O	990	1002	dramatically	dramatically	RB	B-ADVP
O	1003	1011	enhances	enhance	VBZ	B-VP
O	1012	1015	the	the	DT	B-NP
O	1016	1023	overall	overall	JJ	I-NP
O	1024	1035	improvement	improvement	NN	I-NP
O	1036	1038	in	in	IN	B-PP
O	1039	1041	PC	PC	NN	B-NP
O	1041	1042	(	(	(	O
O	1042	1044	20	20	CD	B-NP
O	1044	1045	)	)	)	O
O	1046	1056	associated	associate	VBN	B-VP
O	1057	1061	with	with	IN	B-PP
O	1062	1069	inhaled	inhale	VBN	B-NP
O	1070	1084	corticosteroid	corticosteroid	NN	I-NP
O	1085	1090	usage	usage	NN	I-NP
O	1090	1091	.	.	.	O

O	1092	1095	The	The	DT	B-NP
O	1096	1103	average	average	JJ	I-NP
O	1104	1106	PC	PC	NN	I-NP
O	1106	1107	(	(	(	O
O	1107	1109	20	20	CD	B-NP
O	1109	1110	)	)	)	O
O	1111	1113	at	at	IN	B-PP
O	1114	1119	trial	trial	NN	B-NP
O	1120	1123	end	end	NN	I-NP
O	1124	1127	for	for	IN	B-PP
O	1128	1136	subjects	subject	NNS	B-NP
O	1137	1139	on	on	IN	B-PP
O	1140	1147	inhaled	inhale	VBN	B-NP
O	1148	1163	corticosteroids	corticosteroid	NNS	I-NP
O	1164	1174	possessing	possess	VBG	B-VP
O	1175	1176	a	a	DT	B-NP
O	1177	1184	variant	variant	JJ	I-NP
O	1185	1191	allele	allele	NN	I-NP
O	1192	1195	was	be	VBD	B-VP
O	1196	1198	in	in	IN	B-PP
O	1199	1202	the	the	DT	B-NP
O	1203	1209	normal	normal	JJ	I-NP
O	1210	1215	range	range	NN	I-NP
O	1216	1219	for	for	IN	B-PP
O	1220	1233	nonasthmatics	nonasthmatic	NNS	B-NP
O	1233	1234	.	.	.	O

O	1235	1237	In	In	IN	B-PP
B-Cell	1238	1246	cellular	cellular	JJ	B-NP
O	1247	1253	models	model	NNS	I-NP
O	1253	1254	,	,	,	O
O	1255	1257	we	we	PRP	B-NP
O	1258	1262	show	show	VBP	B-VP
O	1263	1267	that	that	IN	B-SBAR
O	1268	1271	the	the	DT	B-NP
O	1272	1277	TBX21	TBX21	NN	I-NP
O	1278	1285	variant	variant	NN	I-NP
O	1286	1295	increases	increase	VBZ	B-VP
B-Cell	1296	1297	T	T	NN	B-NP
I-Cell	1298	1304	helper	helper	NN	I-NP
I-Cell	1305	1306	1	1	CD	I-NP
O	1307	1310	and	and	CC	O
O	1311	1320	decreases	decrease	VBZ	B-VP
B-Cell	1321	1322	T	T	NN	B-NP
I-Cell	1323	1329	helper	helper	NN	I-NP
I-Cell	1330	1331	2	2	CD	I-NP
O	1332	1340	cytokine	cytokine	NN	I-NP
O	1341	1351	expression	expression	NN	I-NP
O	1352	1362	comparably	comparably	RB	B-ADVP
O	1363	1367	with	with	IN	B-PP
O	1368	1372	wild	wild	JJ	B-NP
O	1373	1377	type	type	NN	I-NP
O	1377	1378	.	.	.	O

O	1379	1384	TBX21	TBX21	NN	B-NP
O	1385	1388	may	may	MD	B-VP
O	1389	1393	thus	thus	RB	I-VP
O	1394	1396	be	be	VB	I-VP
O	1397	1399	an	an	DT	B-NP
O	1400	1409	important	important	JJ	I-NP
O	1410	1421	determinant	determinant	JJ	I-NP
O	1422	1437	pharmacogenetic	pharmacogenetic	JJ	I-NP
O	1438	1446	response	response	NN	I-NP
O	1447	1449	to	to	TO	B-PP
O	1450	1453	the	the	DT	B-NP
O	1454	1461	therapy	therapy	NN	I-NP
O	1462	1464	of	of	IN	B-PP
O	1465	1471	asthma	asthma	NN	B-NP
O	1472	1476	with	with	IN	B-PP
O	1477	1484	inhaled	inhale	VBN	B-NP
O	1485	1500	corticosteroids	corticosteroid	NNS	I-NP
O	1500	1501	.	.	.	O

